KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Merck (MRK) Times Interest Earned (2011 - 2013)

Merck (MRK) reported Times Interest Earned of -$13.09 for Q1 2013, down 49.75% year-over-year from -$26.05 in Q1 2012, and up 11.98% on a QoQ basis from -$14.87 in Q4 2012.

Merck (MRK) has 3 years of Times Interest Earned data on file, last reported at -$13.09 in Q1 2013.

  • Quarterly Times Interest Earned fell 49.75% year-over-year to -$13.09 in Q1 2013, while the trailing twelve-month figure through Dec 2013 was -$62.01 (down 475.24% YoY) and the FY2012 annual result came in at $4.28, up 16.0% from the prior year.
  • Times Interest Earned rose to -$13.09 in Q1 2013 per MRK's latest filing, from -$14.87 in the prior quarter.
  • Across five years, Times Interest Earned topped out at -$8.33 in Q2 2012 and bottomed at -$15.36 in Q2 2011.
  • The 3-year median for Times Interest Earned is -$12.53 (2011), against an average of -$12.23.
  • The widest annual swing landed in 2012, when Times Interest Earned surged 45.81%; it then slumped 49.75% in 2013.
  • Tracing MRK's Times Interest Earned over 3 years: stood at -$15.0 in 2011, then gained by 0.84% to -$14.87 in 2012, then rose by 11.98% to -$13.09 in 2013.
  • Per Business Quant, the three latest MRK Times Interest Earned figures stand at -$13.09 (Q1 2013), -$14.87 (Q4 2012), and -$10.78 (Q3 2012).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Times Interest Earned (Qtr)
1 Novartis Ag 107,124,802.25 Bn 107,124,802.25 Bn - -
2 Eli Lilly 969.00 Bn 963.72 Bn 16.22 Bn -
3 Johnson & Johnson 539.46 Bn 517.41 Bn 15.96 Bn 23.39
4 AbbVie 376.92 Bn 367.57 Bn 10.78 Bn -
5 Merck 285.00 Bn 279.35 Bn 12.09 Bn -
6 Amgen 177.58 Bn 165.55 Bn 5.87 Bn 4.06
7 Gilead Sciences 163.22 Bn 155.50 Bn 5.52 Bn 10.78
8 Pfizer 145.86 Bn 133.09 Bn -1.21 Bn -
9 Bristol Myers Squibb 111.90 Bn 101.44 Bn 8.07 Bn -
10 Gsk 88.34 Bn 83.66 Bn - -

Historic Data

Download Data 🔒
DateValue
Mar 31, 2013 -13.09
Dec 31, 2012 -14.87
Sep 30, 2012 -10.78
Jun 30, 2012 -8.33
Mar 31, 2012 -8.74
Dec 31, 2011 -15.00
Sep 30, 2011 -11.36
Jun 30, 2011 -15.36
Mar 31, 2011 -12.53